Drugs / Opipramol
last change Jan 2019 re-read 2 minutes ago

Opipramol

Small molecule

Developed for
substance abuse
Investigated by
Hannover Medical School

Trials 1 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02374567 Jan 2015 → Jun 2017 anxiety disorder, dementia, depressive disorder, schizophrenia +1 Hannover Medical School Terminated No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03065998 Comparator Mar 2017 → Jan 2018 substance abuse Ministry of Health, Israel Unknown No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Opipramol ClinicalTrials.gov intervention name — accepted as the source's own label NCT02374567
1

NCT03065998

Known as G-33040 ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Known as Insidon ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Known as NSC-169867 ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Known as Opipramol dihydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Known as Opipramol dura ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Known as Opipramol hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Known as OPIPRAMOL HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL370753
Action Activate “Opipramol is a selective agonist for sigma-1 receptor.” NCT03065998
Modality Small molecule CHEMBL370753